Abstract 151P
Background
Depth of response (DpR) and early tumor shrinkage (ETS) are established predictors of overall survival (OS) in colorectal and gastric cancer; however, data for pancreatic cancer (PC) are limited.
Methods
This study was conducted as part of two multicenter retrospective studies (NAPOLEON and NAPOLEON-2) of patients (pts) with measurable advanced PC tumors. Cohort 1 included 292 pts treated with gemcitabine/nab-PTX (GnP, 184 pts) and FOLFIRINOX (FFX, 108 pts) as first-line chemotherapy, and Cohort 2 included 88 pts treated with nanoliposomal irinotecan, fluorouracil and folinic acid as second-line chemotherapy. DpR was defined as the maximum tumor shrinkage percentage on imaging compared with the pre-treatment level. Pts were divided by DpR into three groups: control (Group A), responder (Group B), and deep responder (Group C). ETS was defined as ≥20% reduction from the start of treatment to the second evaluation.
Results
In Cohort 1, DpR was −2.3 to +1550% in Group A, −28.6 to −2.5% in Group B, and −100.0 to −28.6% in Group C. The baseline C-reactive protein/albumin ratio differed significantly by group (p=0.04). The median OS (mOS) was significantly longer in Group C (17.2 months) and Group B (11.5 months) than in Group A (8.4 months), (hazard ratio [HR], 95% confidence interval [CI]: 0.30, 0.22–0.42, p<0.01; and 0.58, 0.43–0.79, p<0.01, respectively). The mOS was also significantly longer in the ETS group overall (HR 0.46, 95% CI 0.35–0.61, p<0.01) and in both the GnP and FFX subgroups. In Cohort 2, DpR was +18.4 to +128.6% in Group A, −2.9 to +17.9% in Group B, and −80.0 to −3.2% in Group C. The baseline prevalence of ascites differed significantly by group (p=0.04). The mOS was significantly longer in Group C (10.9 months) than in Group A (4.6 months; HR 0.33, 95% CI 0.17–0.65, p<0.01), but mOS in Group B (6.8 months) did not differ significantly from Group A (p=0.10).
Conclusions
This is the first report that DpR and ETS might be predictors of OS in pts with PC on standard chemotherapy.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract